These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23861694)

  • 41. Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
    Rodgers-Gray BS; Fullarton JR; Carbonell-Estrany X; Keary IP; Tarride JÉ; Paes BA
    J Med Econ; 2023; 26(1):630-643. PubMed ID: 37067826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A; Galvani AP; Meyers LA
    JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
    Wang DY; Li A; Paes B; Mitchell I; Lanctôt KL;
    Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
    Ratti C; Greca AD; Bertoncelli D; Rubini M; Tchana B
    Ital J Pediatr; 2023 Jan; 49(1):4. PubMed ID: 36631870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Palivizumab for preterm infants. Is it worth it?
    Embleton ND; Harkensee C; Mckean MC
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
    Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CARESS: the Canadian registry of palivizumab.
    Mitchell I; Paes BA; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2011 Aug; 30(8):651-5. PubMed ID: 21343842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A post-incorporation study on the use of palivizumab in the Brazilian public health system.
    Batista JDL; Ferreira MAP; Xavier CDS; Souza ITA; Cruz LN; Polanczyk CA
    Rev Inst Med Trop Sao Paulo; 2021; 63():e5. PubMed ID: 33533808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study.
    Kamori A; Morooka Y; Yamamura K; Chong PF; Kuga N; Takahata Y; Sagawa K; Furuno K
    Medicine (Baltimore); 2021 Nov; 100(47):e27952. PubMed ID: 34964779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.
    Banerji A; Lanctôt KL; Paes BA; Masoud ST; Tam DY; Macdonald WA; Roberts A
    Pediatr Infect Dis J; 2009 Aug; 28(8):702-6. PubMed ID: 19461555
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017).
    Paes BA; Saleem M; Li A; Lanctôt KL; Mitchell I;
    Pediatr Infect Dis J; 2020 Jun; 39(6):539-545. PubMed ID: 32235248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent Trends in RSV Immunoprophylaxis: Clinical Implications for the Infant.
    Acero-Bedoya S; Wozniak PS; Sánchez PJ; Ramilo O; Mejias A
    Am J Perinatol; 2019 Jul; 36(S 02):S63-S67. PubMed ID: 31238362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
    Ordóñez JE; Huertas VM
    BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
    Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
    J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP; Lee SWH
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.